Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 10, 2023, titled "Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials".